Apellis Surges 135% in One Day While Gene Therapy Stocks Crash — 8 Biotech Buys and 12 to Avoid (April 2026)
Our multi-indicator screener scanned 90+ biotech and pharma stocks. APLS exploded, MDGL hit #1 rank, and SGMO collapsed 19%. Here's the full technical breakdown.
by Kowsalya
Published Apr 01, 2026 | Updated Apr 01, 2026 | 📖 8 min read
Article continues below advertisement
On This Page
- Top-Ranked Biotech Buys: The Strongest Setups Right Now
- The 135% Elephant in the Room: APLS (Apellis)
- High-Conviction Buys With Volume Confirmation
- The Monitor Zone: Good Fundamentals, Bad Timing
- Gene Therapy and Small-Cap Biotech: The Damage Report
- Novo Nordisk and the GLP-1 Trade: What the Technicals Say
- The Actionable Watchlist: Best Risk/Reward Setups
- ETF Snapshot: XBI and IBB
- How We Score These Stocks
Biotech just had its wildest session of 2026. Apellis Pharmaceuticals (APLS) rocketed 135% in a single day, Sarepta (SRPT) surged 32.7% on its Rate of Change, and Madrigal (MDGL) quietly earned the highest composite score in our entire biotech universe at +15. Meanwhile, Sangamo (SGMO) cratered 19.35%, and a string of gene therapy names are flashing exit signals.
We ran our proprietary multi-factor screener across 90+ biotech, pharma, and genomics stocks. The model scores each stock from -14 to +15 using 15 technical indicators spanning momentum (RSI, MACD, Stochastic), trend strength (ADX, DI crossovers, Aroon), volume confirmation (OBV, MFI), volatility (ATR, Bollinger Bands), and moving average structure (Golden/Death Cross).
The verdict? A deeply divided sector where a handful of names are in powerful uptrends — and the rest are either dead money or actively collapsing.
Top-Ranked Biotech Buys: The Strongest Setups Right Now
#1 Ranked: MDGL — Madrigal Pharmaceuticals | Score: +15 | $523.47 (+3.6%)
Madrigal owns the top spot in the entire biotech scan with a perfect storm of bullish signals. MACD histogram at +10.92 is the strongest reading in the dataset. ADX at 36.2 confirms a strong trend, +DI dominates -DI (39.0 vs 9.4), OBV is rising, and the stock sits on a Golden Cross. The 17.7% Rate of Change and 20.2% one-month return show serious institutional momentum.
The setup: Price is currently extended above the entry zone — wait for a pullback. Stop at $484.44, targets at $575.52 and $601.54. The screener flagged RSI approaching 70, so tighten stops to breakeven if you're already in.
#2 Ranked (Tied): TERN — Terns Pharmaceuticals | Score: +13 | $52.72 (+0.3%)
Terns has been on a tear — up 25.4% in the past month and 27% over three months. ADX at 38.4 signals a strong trend, +DI leads at 30.2 vs 8.5, OBV is rising, and the Golden Cross is intact. This is a textbook trend continuation setup meeting 4 out of 6 entry conditions at 77% confidence.
The catch: RSI at 75.5 is overbought and Stochastic is at 95.1 — this is take-profit territory, not a fresh entry point. Wait for RSI to cool below 65 before adding.
#2 Ranked (Tied): EWTX — Edgewise Therapeutics | Score: +13 | $31.50 (+4.0%)
Edgewise is one of the cleanest setups in this scan. Golden Cross in place, OBV rising, MACD bullish, +DI leads -DI (25.6 vs 17.1), and the stock is just 1.38% off its high. At a 44.2% historical volatility, it's one of the lower-vol names among the top scorers — meaning your stop loss won't get randomly triggered by noise.
The setup: Entry zone $27.75–$29.97, targets at $34.73 and $36.34, stop at $29.08. R:R of 1.3:1.
#2 Ranked (Tied): SRPT — Sarepta Therapeutics | Score: +13 | $21.76 (+6.3%)
Sarepta is in full trend continuation mode with a 32.7% Rate of Change — the highest momentum reading in the biotech scan. ADX at 29.1 confirms the trend, +DI crushes -DI (38.1 vs 16.4), and OBV is rising. Four out of 6 entry conditions met at 77% confidence. But note the Death Cross is still active and 139% historical volatility means this stock can move violently in both directions.
The setup: Entry zone $13.75–$18.12 (if you missed the initial move), targets at $24.57 and $25.97, stop at $19.66.
The 135% Elephant in the Room: APLS (Apellis)
You can't write about biotech this week without addressing Apellis. The stock exploded 135.4% in a single session, catapulting from the teens to $40.23. RSI hit 87.4 (extremely overbought), MFI reached 89.9 (also overbought), and historical volatility spiked to an absurd 485%. The CCI reading of 617.6 is the most extreme in our entire database.
Our screener scores it +11 with a trend continuation entry — but immediately flags "TAKE PROFIT" due to the extreme overbought conditions. If you rode this move, the data says lock in gains. If you're thinking about chasing, the screener says wait for a pullback. There is no support structure at these levels — the stock went vertical.
High-Conviction Buys With Volume Confirmation
Beyond the top-ranked names, these stocks met 4+ entry conditions with rising OBV — the combination that historically produces the most reliable follow-through:
| Ticker | Company | Price | Score | Entry Zone | Target 1 | Stop Loss | Key Signal |
|---|---|---|---|---|---|---|---|
| TGTX | TG Therapeutics | $33.22 | +11 | Extended — wait | $36.07 | $31.08 | Trend continuation, 77% conf |
| INSM | Insmed | $163.52 | +11 | Extended — wait | $177.29 | $153.19 | Breakout, RSI 64 — tighten stop |
| PTGX | Protagonist | $105.40 | +11 | $90.32–$97.88 | $114.91 | $98.27 | At all-time high, RSI 66 |
| AGIO | Agios | $33.83 | +11 | Extended — wait | $36.93 | $31.50 | RSI 76 overbought — tighten stop |
| FOLD | Amicus | $14.46 | +11 | $14.31–$14.39 | $14.52 | $14.41 | ADX 64 — monster trend, take profit |
| SMMT | Summit | $18.96 | +9 | Extended — wait | $20.97 | $17.46 | +22% in 1 week, RSI 67 |
| TWST | Twist Bioscience | $47.52 | +10 | $41.73–$45.84 | $53.92 | $42.72 | OBV rising, Golden Cross, +44.7% 3M |
| SNY | Sanofi | $48.18 | +7 | Extended — wait | $50.15 | $46.70 | RSI 66, +DI dominates (38.8 vs 17.8) |
Notice a pattern? Many of the top-scoring names are already extended above their entry zones. This tells you the move has started — you either got in early or you wait for the pullback. Chasing overbought biotech stocks is how portfolios blow up.
The Monitor Zone: Good Fundamentals, Bad Timing
Several well-known pharma names scored positively but lack enough entry conditions to justify fresh capital right now:
| Ticker | Price | Score | R:R | Status |
|---|---|---|---|---|
| REGN | $772.64 | +6 | 1.3:1 | Stochastic 96.5 overbought — wait for pullback |
| BMY | $60.65 | +6 | 1.3:1 | Stochastic 89.7 overbought, Golden Cross intact |
| ABBV | $217.49 | +4 | 1.3:1 | Only 2/6 conditions met — needs more confirmation |
| ALNY | $330.87 | +5 | 1.3:1 | 4 conditions met but Death Cross active |
| IONS | $75.09 | +9 | 0.9:1 | Strong setup, weak R:R at current levels |
LLY (Eli Lilly) is worth a special mention. Despite being the most-watched pharma stock in the market, it scores just -1 with only 1 out of 6 entry conditions met. It's 17.1% off its high, -DI leads +DI (31.6 vs 19.3), and the one-month return is -9.65%. The Golden Cross is the only bullish signal left standing. Wait for ADX to flip bullish and +DI to reclaim dominance before considering an entry.
Gene Therapy and Small-Cap Biotech: The Damage Report
The gene therapy and small-cap biotech space is in rough shape. Several names are flashing EXIT NOW signals — meaning the composite score is deeply negative and ADX confirms trending downward momentum:
| Ticker | Price | Score | %Off High | 3M Return | Signal |
|---|---|---|---|---|---|
| SGMO | $0.25 | -14 | -66.2% | -39.0% | EXIT — RSI 27 oversold, CCI -272 |
| MDXH | $2.30 | -14 | -54.0% | -31.3% | EXIT — Triple oversold (RSI/Stoch/MFI) |
| KALA | $0.17 | -13 | -99.1% | -70.7% | EXIT — Sub-penny territory, triple oversold |
| OGEN | $0.56 | -12 | -88.6% | -31.7% | EXIT — ADX 25 confirms downtrend |
| RXRX | $3.07 | -10 | -54.8% | -25.7% | EXIT — ADX 26 confirms downtrend |
| RCKT | $3.58 | -10 | -32.5% | +2.9% | AVOID — ROC -24.3%, CCI -185 |
| SANA | $2.88 | -9 | -51.4% | -30.1% | EXIT — Down 30.6% in one month |
| PHGE | $3.75 | -9 | -69.6% | +87.5% | AVOID — Stochastic 5.1, 3M gain evaporating |
SGMO (Sangamo Therapeutics) deserves special attention. It dropped 19.35% on the day, carries the worst score in the entire scan at -14, and trades at just $0.25 — down 66% from its highs. RSI at 26.6 is oversold, CCI at -272 is the most extreme negative reading in the dataset, and it's trading below its lower Bollinger Band. The Death Cross is active and every single momentum indicator is bearish. This is not a "buy the dip" situation — this is a stock in capitulation.
Novo Nordisk and the GLP-1 Trade: What the Technicals Say
NVO (Novo Nordisk) scores -5 with a SELL signal. The stock is down 54.7% from its highs — a stunning decline for what was once the most crowded trade in pharma. ADX at 37.1 confirms a strong downtrend, -DI dominates +DI (34.9 vs 19.0), and the Death Cross is active. OBV is falling, meaning institutional money is still exiting. The only bullish signal is the MACD just flipped positive, but with only 3 out of 6 conditions met and a terrible 0.4:1 risk-reward ratio, this is a watch-and-wait situation.
Compare that to LLY at -1 — Lilly is at least holding its Golden Cross and sitting closer to its 200-day SMA. If you want GLP-1 exposure, the technicals marginally favor Lilly over Novo, but neither is actionable right now.
The Actionable Watchlist: Best Risk/Reward Setups
Cutting through all the noise, here are the biotech stocks that combine a positive score with a reasonable entry zone (not extended) and at least 1.3:1 risk-reward:
| Ticker | Price | Score | Entry Zone | Target 1 | Stop | Why It Works |
|---|---|---|---|---|---|---|
| EWTX | $31.50 | +13 | $27.75–$29.97 | $34.73 | $29.08 | Golden Cross, rising OBV, low vol for biotech |
| TWST | $47.52 | +10 | $41.73–$45.84 | $53.92 | $42.72 | Golden Cross, rising OBV, +44.7% 3M momentum |
| ZEAL | $295.00 | 0 | $221.80–$286.67 | $354.71 | $269.24 | Best R:R in scan at 2.3:1, MACD turning |
| KYMR | $83.29 | +8 | $74.39–$80.48 | $92.15 | $76.65 | Golden Cross, rising OBV, 4 conditions met |
| PTGX | $105.40 | +11 | $90.32–$97.88 | $114.91 | $98.27 | At all-time high, Golden Cross, bullish DI |
| DAWN | $21.44 | +10 | $15.25–$20.49 | $22.33 | $20.77 | ADX 58 = strongest trend in scan, +107% 1M |
ZEAL stands out as a contrarian pick — it only scores 0 and is down 45.9% from its high, but it offers the best risk-reward ratio in the entire biotech scan at 2.3:1. The MACD has turned bullish with a histogram of +6.14, and 4 out of 6 entry conditions are met. If you're looking for asymmetric upside with a defined stop, this is the setup to watch.
ETF Snapshot: XBI and IBB
XBI (SPDR S&P Biotech ETF) scores +6 with a STRONG BUY signal. The MACD just flipped bullish, +DI leads -DI (28.4 vs 24.9), and the Golden Cross is intact. It's only 2.9% off its high. Entry zone sits at $117.88–$123.34 with a $135.36 target. This is the broadest bullish signal in the sector.
IBB (iShares Biotechnology ETF) also scores +4 with similar bullish signals but slightly weaker internals — -DI still narrowly leads +DI (27.1 vs 25.1). Both ETFs are in better shape than the semiconductor ETFs (SMH and SOXX both score negative), suggesting biotech is the stronger sector right now.
LABU (3x Bull Biotech ETF) scores +6 and met 4 entry conditions, but remember — this is a leveraged product with 121.7% historical volatility. It surged 22.3% in a single session. Only for traders with strict stop-loss discipline.
How We Score These Stocks
Our composite score aggregates 15 technical indicators across five dimensions: Momentum (RSI, MACD histogram, Stochastic %K), Trend (ADX strength, +DI/-DI crossovers, Aroon Up/Down), Volume (OBV trend, Money Flow Index), Volatility (Bollinger Band position, historical volatility), and Structure (Golden/Death Cross, SMA50 vs SMA200, distance from highs). Entry conditions require 3–6 simultaneous confirmations. Risk-reward ratios use ATR-based stops and Fibonacci-extension targets.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice. All data is based on technical analysis as of market close on March 31, 2026. Technical indicators reflect historical price action and do not guarantee future results. Always conduct your own research and consult a qualified financial advisor before making investment decisions. The author and MarketsHost may hold positions in some of the securities discussed.
Related Articles
Disclaimer : The above information is for general informational purposes only. All information on the Site is provided in good faith, however we make no representation or warranty of any kind, express or implied, regarding the accuracy, adequacy, validity, reliability, availability or completeness of any information on the Site.